Back
Esperion Therapeutics 10K Form
Sell
25
ESPR
Esperion Therapeutics
Last Price:
1.69
Seasonality Move:
4.86%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2003-11-10 | 10Q | ESPR/Esperion Therapeutics Quarterly |
2003-10-28 | 10Q | ESPR/Esperion Therapeutics Quarterly |
2003-08-14 | 10Q | ESPR/Esperion Therapeutics Quarterly |
2003-03-26 | 10K | ESPR/Esperion Therapeutics Annual |
2002-03-19 | 10K | ESPR/Esperion Therapeutics Annual |
2002-03-14 | 10K | ESPR/Esperion Therapeutics Annual |
Receive ESPR News And Ratings
See the #1 stock for the next 7 days that we like better than ESPR
ESPR Financial Statistics
Sales & Book Value
Annual Sales: | $116.33M |
---|---|
Cash Flow: | $-7.28M |
Price / Cash Flow: | 0 |
Annual Sales: | $-1.77 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -0.86000 |
---|---|
Net Income (TTM): | $-98.5M |
Gross Margin: | $73.07M |
Return on Equity: | 0% |
Return on Assets: | -35.51% |
Esperion Therapeutics Earnings Forecast
Key Esperion Therapeutics Financial Ratios
- The Gross Profit Margin over the past 17 years for ESPR is 62.81%.
- The Selling, General & Administrative Expenses for ESPR have been equal to 122.51% of Gross Profit Margin.
- The Research & Development expenses have been 74.02% of Revenue.
- The Interest Expense is -28.18% of Operating Income.
- The Net Earning history of ESPR is -179.87% of Total Revenues.
- Per Share Earnings over the last 17 years have been positive in 6 years.
Esperion Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | ESPR |
CUSIP: | 29664W |
Website: | esperion.com |
Debt
Debt-to-Equity Ratio: | -0.76 |
---|---|
Current Ratio: | 1.97 |
Quick Ratio: | 1.42 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
ESPR Technical Analysis vs Fundamental Analysis
Sell
25
Esperion Therapeutics (ESPR)
is a Sell
Is Esperion Therapeutics a Buy or a Sell?
-
Esperion Therapeutics stock is rated a Sell
The current Esperion Therapeutics [ESPR] share price is $1.69. The Score for ESPR is 25, which is 50% below its historic median score of 50, and infers higher risk than normal.